Hi supergrass, Your thoughts were mirrored in discussion when Chair Ewen took up the Anteotech leadership, -then again on David’s appointment. I feel that pharmaceutical is a complex sector to break into on a worldwide front. 25% for ownership of the expanding platform for accurate multiplex technology, joint ventured with Merck to rollout the approvals, production, and sales appeals to me as well worth consideration. Thankfully Ewen and David have the experience to operate effectively in the JV space, however extensive time could be required to canvas and negotiate with a suitor.
At this point, ‘phones and emails are buzzing in search of clues for “wot’s going on?”. Fortunately for those attending the November AGM the confidence as radiated in Directors and senior management was directly planted. The physical confidence held in high quality placements for those serving in the Anteotech board and management team is carrying me through this holiday space. For Anteo, apart from statutory and well deserved breaks, I believe that the bases in critical action would be well covered. Manuel has completed Anteo’s presentations March in Florida September in Europe and December in San Diego highlighting developments that will have generated serious interest from battery royalty. Management have 14 business days to prepare the exciting quarterly I expect. In the meantime, Government will be considering funding for technology in clean energy and health sectors and negotiations with interested battery suitors can resume. Best wishes to all for the exciting year I believe is coming our way.
ADO Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
